

1308-101 A

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
REQUEST FOR FILING APPLICATION UNDER RULE 60**



07/15/97

Pursuant to 37 CFR 1.60, please file a

☐ continuation ☒ divisional

of the pending prior PATENT APPLICATION of:

Inventor: SCHNEIDER et al

Serial No. 08/456,385

Filed: July 15, 1997

For: STABLE MICROBUBBLES SUSPENSIONS
INJECTABLE INTO LIVING ORGANISMSHon. Commissioner of Patents and Trademarks
Washington, DC 20231

Sir:

This request for filing under Rule 60 is made by the following named inventor(s) (using the above-identified title):

Inventor(s): SCHNEIDER et al

- ☒ Attached is a true copy of the prior application as originally filed including the specification, claims, Oath/Declaration and drawings (if any) and abstract (if any). No amendments (if any) referenced in the Oath or Declaration filed to complete the prior application introduced new matter.
- ☒ Priority is hereby claimed under 35 USC 119 based on the following foreign applications:

Application Number

90810262.7

PCT/EP91/00620

Country

Europe

Europe

Day/Month/Year Filed

4/2/90

4/2/91

☒ certified copy(ies) of foreign application(s) attached or☐ already filed on _____ in prior appln no. _____☒ already filed in PCT/EP91/00620

filed

filed 4/2/91

☒ The prior application is assigned to Bracco International B.V.☒ Power of Attorney has been granted to Arthur R. Crawford et al, Reg. No. 25,327 of Nixon & Vanderhye P.C., 1100North Glebe Road, 8th Floor, Arlington, Virginia 22201. Address all future communications to this address.☒ Address all future communications to: Nixon & Vanderhye P.C., 1100 North Glebe Road, 8th Floor, Arlington, Virginia 22201.☒ Please amend the specification by inserting before the first line -This is a rule 60 division of application Serial No. 08/456,385, filed June 1, 1995, which is a division of 08/315,347 filed September 30, 1994 which is a division of 08/128,540 filed September 29, 1993 now Patent 5,380,519,☐ Petition filed in prior application to extend its life to insure copendency.☒ The Examiner's attention is directed to the prior art cited in the parent application by applicant and/or Examiner for the reasons stated therein.☒ Please enter the attached and/or below preliminary amendment **prior** to calculation of filing fee:

Attached: Preliminary Amendment and Information Disclosure Statement

FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY HEREWITH CANCELED

Basic Filing Fee			\$	770.00
Total effective claims	29	- 20 (at least 20) =	9 x \$ 22.00	\$ 198.00
Independent claims	6	- 3 (at least 3) =	3 x \$ 80.00	\$ 240.00
If any proper multiple dependent claims now added for first time, add \$260.00 (ignore improper)				\$
SUBTOTAL				\$ 1208.00
Assignment Recording Fee (\$40.00)			\$	
TOTAL FEE ENCLOSED				\$ 1208.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Account No. 14-1140**. A duplicate copy of this sheet is attached.

1100 North Glebe Road
8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
ARC:pfrc

NIXON & VANDERHYE P.C.

For Atty: Arthur R. Crawford, Reg. No. 25,327

Signature: _____

By: Leonard C. Mitchard, Reg. No. 29,009

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

SCHNEIDER et al

Atty. Ref.: **1201-45**

Serial No. **to be assigned**

Group:

Filed: **July 15, 1997**

Examiner:

For: **STABLE MICROBUBBLES SUSPENSIONS
INJECTABLE INTO LIVING ORGANISMS**

* * * * *

July 15, 1997

Honorable Commissioner of Patents
and Trademarks
Washington, DC 20231

Sir:

**PRELIMINARY AMENDMENT REQUESTING INTERFERENCE
WITH PATENT UNDER 37 C.F.R. § 1.607**

Applicants seek to add claims to this application and have an interference declared between this application and a United States patent, and thus comply with 37 C.F.R. § 1.607, "Request by Applicant for Interference With Patent," as follows:

AMENDMENT

IN THE CLAIMS

Cancel claims 1 through 27.

Please add the following new claims:

--28. Gas microbubbles comprising an amphiphilic surfactant capable of forming gas-containing microbubbles in an aqueous carrier liquid, the microbubbles of a biocompatible halogenated gas or air are bounded by a gas/liquid interface which comprises as the amphiphilic surfactant at least one saturated phospholipid in lamellar or laminar form.

29. The gas microbubbles as claimed in claim 28, wherein said halogenated gas is a freon.

30. The gas microbubbles as claimed in claim 29, wherein said freon is a perfluorinated hydrocarbon.

31. The gas microbubbles as claimed in claim 28, wherein said phospholipid has hydrophilic groups selected from the group consisting of choline, ethanolamine, serine, glycerol, pentoses and hexoses.

32. The gas microbubbles as claimed in claim 28, wherein the phospholipid is selected from phosphatidic acid, phosphatidylcholine,

phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, cardiolipin and sphingomyelin.

33. The gas microbubbles as claimed in claim 28, wherein the surfactant further contains substances selected from dicetylphosphate, cholesterol, ergosterol, phytosterol, sitosterol, lanosterol, tocopherol, propyl gallate, ascorbyl palmitate and butylated hydroxy-toluene.

34. The gas microbubbles as claimed in claim 28, wherein said surfactant comprises a lecithin or derivative thereof.

35. The gas microbubbles as claimed in claim 28, wherein the microbubbles containing fluorinated gas are stabilized by monolayers of said surfactant.

36. The gas microbubbles as claimed in claim 28, having an average size of 0.1-10 μm .

37. An aqueous dispersion comprising gas microbubbles as claimed in claim 28.

38. An aqueous dispersion comprising gas microbubbles as claimed in claim 29.

39. An aqueous dispersion comprising gas microbubbles as claimed in claim 30.

40. An aqueous dispersion comprising gas microbubbles as claimed in claim 31.

41. An aqueous dispersion comprising gas microbubbles as claimed in claim 28, containing dissolved viscosity enhancers or stabilizers selected from linear and cross-linked poly- and oligo-saccharides, sugars, hydrophilic polymers and iodinated compounds in a weight ratio to the surfactants comprised between about 1:5 to 100:1.

42. Aqueous dispersion as claimed in claim 41, further comprising up to 50% by weight of non-lamellar surfactants selected from fatty acids, esters and ethers of fatty acids and alcohols with polyols.

43. Aqueous dispersion as claimed in claim 42, wherein the polyols are polyalkylene glycols, polyalkylenated sugars and other carbohydrates and polyalkylenated glycerol.

44. Aqueous dispersion comprising gas microbubbles as claimed in claim 28, containing 10^7 - 10^8 microbubbles/ml.

45. Aqueous dispersion comprising gas microbubbles as claimed in claim 28, containing 10^8 - 10^9 microbubbles/ml.

46. Aqueous dispersion comprising gas microbubbles as claimed in claim 28, containing 10^{10} - 10^{11} microbubbles/ml.

47. A process for preparation of a contrast agent which comprises generating gas microbubbles comprising amphiphilic phospholipid material capable of formation of gas-containing vesicles in aqueous carrier liquid, said microbubbles containing a biocompatible halogenated gas.

48. A process as claimed in claim 47 which comprises shaking or sonicating an amphiphile-containing mixture comprising a phospholipid in the presence of a halogenated gas to generate a liquid dispersion of said gas microbubbles.

49. A process as claimed in claim 48, wherein an aqueous amphiphile-containing mixture comprising a saturated phospholipid is used to generate an aqueous dispersion of air or gas microbubbles.

50. A process as claimed in claim 48, wherein the contrast agent is isolated by freeze drying.

51. A process as claimed in claim 47, wherein said hydrocarbon is perfluorinated.

52. A contrast agent prepared by the process of claim 47.

53. A method of enhancing ultrasound images of a vascular system comprising administering to said system a diagnostic ultrasound contrast agent according to claim 52.

54. Microbubbles comprising an amphiphilic phospholipid material capable of formation of gas-containing microbubbles, said microbubbles comprising a physiologically acceptable gas.

55. Microbubbles comprising an amphiphilic phospholipid material capable of formation of gas-containing microbubbles, said microbubbles comprising a fluorine-containing gas.

56. Microbubbles comprising an amphiphilic phospholipid material capable of formation of gas-containing microbubbles, said microbubbles comprising a fluorine-containing freon.--

APPLICANTS' REQUEST FOR AN INTERFERENCE WITH A PATENT

1. Identification of Patent under Rule 607(a)(1)

Applicants seek an interference between this application and United States Patent No. 5,536,490 to Klaveness et al (hereinafter the '490 patent) which issued on July 16, 1996.

2. Presentation of a proposed Count Under Rule 607(a)(2)

For purposes of this rule, the following proposed count is believed to define overlapping, patentably indistinct subject matter between this application and the '490 patent:

Count 1

Microbubbles comprising an amphiphilic phospholipid material capable of formation of gas-containing microbubbles, said microbubbles comprising a physiologically acceptable gas.

3. Identification of Claims from the '490 Patent that Correspond to the Proposed Count under Rule 607(a)(3)

Proposed Count	'490 Patent Claims that Correspond to Proposed Count
Count 1	3-5, 17, 19-20

4. Compliance with Rule 607(a)(4)

a. Presentation of New Claims Corresponding to the Proposed Count under Rule 607(a)(4)

Applicants have added new claims 54-56 which are believed to correspond to Count 1, i.e., define patentably indistinct subject matter.

b. Explanation of Why Each Claim Corresponds to the Proposed Count

i) Applicants' Claims Corresponding to Count 1

Claim 54 corresponds exactly to proposed Count 1.

Claims 55 and 56 substantially correspond to Count 1. These claims differ from Count 1 by reciting "fluorine-containing gas" and "freon", respectively, instead of the "physiologically acceptable gas" of Count 1. However, claims 55 and 56 define subsets of Count 1 because both "fluorine-containing gas" and "freon" are subsets of Count 1's "physiologically acceptable gas."

This is demonstrated by Applicants' specification at page 15, lines 22-25 which states that:

"The gases in the microbubbles of the present invention can include, in addition to current innocuous physiologically acceptable gases like CO₂, nitrogen, N₂O, methane, butane, freon and mixtures thereof..." (emphasis added).

The gases defined by "fluorine-containing gases" include "freon". *Hawley's Condensed Chemical Dictionary*, Twelfth Edition, Revised by Richard J. Lewis, Sr., Van Nostrand Reinhold Co., New York.

The '490 patent at column 2, lines 29-34 includes a similar definition:

Any biocompatible gas may be employed in the contrast agents of the invention, for example air, nitrogen, oxygen, hydrogen, nitrous oxide, carbon dioxide, helium, argon, sulphur hexafluoride and low molecular weight optionally fluorinated hydrocarbons such as methane, acetylene or carbon tetrafluoride...(emphasis added).

ii. The '490 Claims Corresponding to Count 1

Claim 3 of the '490 patent is the same as Count 1 except for its recitation of sulphur hexafluoride as its physiologically acceptable gas. Applicants submit that for the reasons stated in Section 4, b, i, *supra*, sulphur hexafluoride (SF₆) recited in certain of the '490 patent claims, e.g., '490 patent claim 3, is an immaterial limitation for purposes of this analysis, i.e., it can be disregarded in evaluating the separate or common patentability of the '490 patent claims and e.g., claims 54-56 of this application. The other claims that correspond to Count 1 of the '490 patent (4-5, 17 and 19-20) relate to specific, patentably indistinct aspects of the microbubbles which are all encompassed by Count 1.

5. Application of the Terms of Applicants' Claims 54-56 Which Correspond to Proposed Count 1 to Applicants' Specification Under Rule 607(a)(5)

<u>Claims</u>	<u>Citations to Applicants' Specification (and Parent Application EP 90810262.7 in parentheses)¹</u>
Microbubbles comprising	the suspension of microbubbles according to the invention at p. 6, l. 27-28 (p. 5, l. 26-27)
an amphiphilic phospholipid material	amphipatic compounds...particularly phospholipids at p. 6, l. 4 and 7 (p. 5, l. 15-20)
capable of formation of gas-containing microbubbles	then air or a gas is introduced into the liposome solution so that a suspension of microbubbles will form at p. 6, l. 36-p. 7, l. 1 (p. 5, l. 35-36)
said microbubbles comprising a physiologically acceptable gas (Claim 54); fluorine-containing gas (Claim 55); freon (Claim 56)	the gases in the microbubbles of the present invention can include in addition to current innocuous physiologically acceptable gases like...freon at p. 15, l. 22-24 (p. 14, l. 11-13)

The citations to EP 90810262.7, Applicants' parent application, demonstrate that Applicants are entitled to the benefit of this EP application for claims 54-56.

6. Explanation of Compliance with 35 U.S.C. § 135(b) Under Rule 607(a)(6)

This request for an interference complies with 35 U.S.C. § 135(b) because it has been filed on July 15, 1997 which is within one year of the July 16, 1996 issue

¹ Copies of Schneider et al's foreign application EP 90810262.7, are attached hereto.

date of the '490 patent, and it adds claims that are the same or substantially the same as claims in the '490 patent.

7. Other Interfering, Patentably Indistinct Subject Matter

The '490 patent has claims directed to other subject matter which is disclosed and claimed in Applicants' application. The table below summarizes the patentably indistinct subject matter:

<u>'490 Claimed Subject matter</u>	<u>'490 Claims</u>	<u>Applicants' Claims</u>	<u>Support for Applicants' Claims in Applicants' Specification (and Parent Application EP90810262.7 in parentheses)</u>
Aqueous dispersion	6-8	10-19	See chart on page 4 herein and aqueous dispersion at pp. 1, 5-6, 13-14, specific phospholipid and additives at pp. 9-11, and microbubble concentration at pp. 12-14 of the disclosure (pp. 1, 4-6, 9-13)
Process for preparing a contrast agent	29-32	20-24	See chart on page 4 herein and process variables at pp. 1, 5-13 of the disclosure (pp. 1, 4-14)
Contrast Agent prepared by a process	38	25	See chart on page 4 herein and contrast agent at pp. 1, 14-15 and the examples of the disclosure pp. 1, 13-14 (p.1 and examples)
Method of enhancing images of vascular system	40	26	See chart on page 4 herein and method of enhancing at pp. 1, 14-15 and the examples of the disclosure (p. 1 and examples)

The citations to EP 90810262.7, Applicants' parent application, demonstrate that Applicants are entitled to the benefit of this EP application for claims 10-26.

Four counts directed to this subject matter should be '490 claims 6, 29, 38 and 40, respectively, (1) written in independent claim form, and (2) with "physiologically acceptable gas" substituted for "sulphur hexafluoride". The counts would encompass all of the subject matter of the '490 claims and Applicants' claims which are identified above -- the differences between the claims and these counts are all recitations of more specific, patentably indistinct, elements of the counts. For example, the sulphur hexafluoride of the '490 claims is patentably indistinct from the physiologically acceptable gas of the counts (see discussion *supra* regarding proposed Count 1). Section 135(b) is complied with for these new counts and claims for the reasons stated in Section 6, *supra*.


Please examine this application and act on this amendment with special dispatch as provided by 37 C.F.R. 1.607(b).

SCHNEIDER et al
Serial No. to be assigned

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____


Leonard C. Mitchard Reg. No. 29,009

for Arthur R. Crawford

Reg. No. 25,327

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

U.S. PATENT APPLICATION

Inventor(s): Michel SCHNEIDER
Daniel BICHON
Philippe BUSSAT
Jerome PUGINIER
Eva HYBL-SUTHERLAND

Invention: STABLE MICROBUBBLES SUSPENSIONS INJECTABLE
INTO LIVING ORGANISMS

NIXON & VANDERHYE P.C.
ATTORNEYS AT LAW
1100 NORTH GLEBE ROAD
8TH FLOOR
ARLINGTON, VIRGINIA 22201-4714
(703) 816-4000
Telex 200797 NIXN UR
Telecopier (703) 816-4100

SPECIFICATION

STABLE MICROBUBBLES SUSPENSIONS INJECTABLE INTO LIVING ORGANISMS

The present invention concerns media adapted for injection into living bodies, e.g. for the purpose of ultrasonic echography and, more particularly, injectable liquid compositions comprising microbubbles of air or physiologically acceptable gases as stable dispersions or suspensions in an aqueous liquid carrier. These compositions are mostly usable as contrast agents in ultrasonic echography to image the inside of blood-stream vessels and other cavities of living beings, e.g. human patients and animals. Other uses however are also contemplated as disclosed hereafter.

The invention also comprises dry compositions which, upon admixing with an aqueous carrier liquid, will generate the foregoing sterile suspension of microbubbles thereafter usable as contrast agent for ultrasonic echography and other purposes.

It is well known that microbodies like microspheres or microglobules of air or a gas, e.g. microbubbles or microballoons, suspended in a liquid are exceptionally efficient ultrasound reflectors for echography. In this disclosure the term of "microbubble" specifically designates air or gas globules in suspension in a liquid which generally results from the introduction therein of air or a gas in divided form, the liquid preferably also containing surfactants or tensides to control the surface properties thereof and the stability of the bubbles. More specifically, one may consider that the internal volume of the microbubbles is limited by the gas/liquid interface, or in other words, the microbubbles are only bounded by a rather evanescent envelope involving the molecules of the liquid and surfactant loosely bound at the gas to liquid junction boundary.

In contrast, the term of "microcapsule" or "microballoon" designates preferably air or gas bodies with a material boundary or envelope formed of molecules other than that of the liquid of suspension, e.g. a polymer membrane wall. Both microbubbles and

and the like) in aqueous solutions of glycols or polyglycols, or other water soluble polymers.

Also, in EP-A- 123.235 and 122.624 (Schering, see also EP-A- 320.433) use is made of air trapped in solids. For instance, 122.624 claims a liquid carrier contrast composition for ultrasonic echography containing microparticles of a solid surfactant, the latter being optionally combined with microparticles of a non-surfactant. As explained in this document, the formation of air bubbles in the solution results from the release of the air adsorbed on the surface of the particles, or trapped within the particle lattice, or caught between individual particles, this being so when the particles are agitated with the liquid carrier.

EP-A- 131.540 (Schering) also discloses the preparation of microbubbles suspensions in which a stabilized injectable carrier liquid, e.g. a physiological aqueous solution of salt, or a solution of a sugar like maltose, dextrose, lactose or galactose, without viscosity enhancer, is mixed with microparticles (in the 0.1 to 1 μ m range) of the same sugars containing entrapped air. In order that the suspension of bubbles can develop within the liquid carrier, the foregoing documents recommend that both liquid and solid components be violently agitated together under sterile conditions; the agitation of both components together is performed for a few seconds and, once made, the suspension must then be used immediately, i.e. it should be injected within 5 - 10 minutes for echographic measurements; this indicates that the bubbles in the suspensions are not longlived and one practical problem with the use of microbubbles suspensions for injection is lack of stability with time. The present invention fully remedies this drawback.

In US-A- 4,466,442 (Schering), there is disclosed a series of different techniques for producing suspensions of gas microbubbles in a liquid carrier using (a) a solution of a tenside (surfactant) in a carrier liquid (aqueous) and (b) a solution of a viscosity enhancer as stabilizer. For generating the bubbles, the techniques used there include forcing at high velocity a mixture of (a), (b) and air through a small aperture; or

0803571.071597

injecting (a) into (b) shortly before use together with a physiologically acceptable gas; or adding an acid to (a) and a carbonate to (b), both components being mixed together just before use and the acid reacting with the carbonate to generate CO₂ bubbles; or adding an over-pressurized gas to a mixture of (a) and (b) under storage, said gas being released into microbubbles at the time when the mixture is used for injection.

The tensides used in component (a) of US-A- 4,466,442 comprise lecithins; esters and ethers of fatty acids and fatty alcohols with polyoxyethylene and polyoxyethylated polyols like sorbitol, glycols and glycerol, cholesterol; and polyoxy-ethylene-polyoxypropylene polymers. The viscosity raising and stabilizing compounds include for instance mono- and polysaccharides (glucose, lactose, sucrose, dextran, sorbitol); polyols, e.g. glycerol, polyglycols; and polypeptides like proteins, gelatin, oxypolygelatin, plasma protein and the like.

In a typical preferred example of this document, equivalent volumes of (a) a 0.5% by weight aqueous solution of Pluronic® F-68 (a polyoxypropylene-polyoxyethylene polymer) and (b) a 10% lactose solution are vigorously shaken together under sterile conditions (closed vials) to provide a suspension of microbubbles ready for use as an ultrasonic contrast agent and lasting for at least 2 minutes. About 50% of the bubbles had a size below 50 μ m.

Although the achievements of the prior art have merit, they suffer from several drawbacks which strongly limit their practical use by doctors and hospitals, namely their relatively short life-span (which makes test reproducibility difficult), relative low initial bubble concentration (the number of bubbles rarely exceeds 10^4 - 10^5 bubbles/ml and the count decreases rapidly with time) and poor reproducibility of the initial bubble count from test to test (which also makes comparisons difficult). Also it is admitted that for efficiently imaging certain organs, e.g. the left heart, bubbles smaller than 50 μ m, preferably in the range of 0.5-10 μ m, are required; with longer bubbles, there are risks of clots and consecutive emboly.

Furthermore, the compulsory presence of solid microparti-

00000001-071507

cies or high concentrations of electrolytes and other relatively inert solutes in the carrier liquid may be undesirable physiologically in some cases. Finally, the suspensions are totally unstable under storage and cannot be marketed as such; hence great skill is required to prepare the microbubbles at the right moment just before use.

Of course there exists stable suspensions of microcapsules, i.e. microballoons with a solid, air-sealed rigid polymeric membrane which perfectly resist for long storage periods in suspension, which have been developed to remedy this shortcoming (see for instance K.J. Widder, EP-A- 324.938); however the properties of microcapsules in which a gas is entrapped inside solid membrane vesicles essentially differ from that of the gas microbubbles of the present invention and belong to a different kind of art; for instance while the gas microbubbles discussed here will simply escape or dissolve in the blood-stream when the stabilizers in the carrier liquid are excreted or metabolized, the solid polymer material forming the walls of the aforementioned micro-balloons must eventually be disposed of by the organism being tested which may impose a serious afterburden upon it. Also capsules with solid, non-elastic membrane may break irreversibly under variations of pressure.

The composition of the present invention, as defined in claim 1, fully remedies the aforementioned pitfalls.

The term "lamellar form" defining the condition of at least a portion of the surfactant or surfactants of the present composition indicates that the surfactants, in strong contrast with the microparticles of the prior art (for instance EP-A-123.235), are in the form of thin films involving one or more molecular layers (in laminate form). Converting film forming surfactants into lamellar form can easily be done for instance by high pressure homogenization or by sonication under acoustical or ultrasonic frequencies. In this connection, it should be pointed out that the existence of liposomes is a well known and useful illustration of cases in which surfactants, more particularly lipids, are in lamellar form.

Liposome solutions are aqueous suspensions of microscopic

089337X.071597

vesicles, generally spherically shaped, which hold substances encapsulated therein. These vesicles are usually formed of one or more concentrically arranged molecular layers (lamellae) of amphipatic compounds, i.e. compounds having a lipophobic hydrophilic moiety and a lipophilic hydrophobic moiety. See for instance "Liposome Methodology", Ed. L.D. Leserman et al, Inserm 136, 2-8 May 1982). Many surfactants or tensides, including lipids, particularly phospholipids, can be laminarized to correspond to this kind of structure. In this invention, one preferably uses the lipids commonly used for making liposomes, for instance the lecithins and other tensides disclosed in more detail hereafter, but this does in no way preclude the use of other surfactants provided they can be formed into layers or films.

It is important to note that no confusion should be made between the present invention and the disclosure of Ryan (US-A-4,900,540) reporting the use of air or gas filled liposomes for echography. In this method Ryan encapsulates air or a gas within liposomic vesicles; in embodiments of the present invention microbubbles or air or a gas are formed in a suspension of liposomes (i.e. liquid filled liposomes) and the liposomes apparently stabilize the microbubbles. In Ryan, the air is inside the liposomes, which means that within the bounds of the presently used terminology, the air filled liposomes of Ryan belong to the class of microballoons and not to that of the microbubbles of the present invention.

Practically, to achieve the suspensions of microbubbles according to the invention, one may start with liposomes suspensions or solutions prepared by any technique reported in the prior art, with the obvious difference that in the present case the liposomic vesicles are preferably "unloaded", i.e. they do not need to keep encapsulated therein any foreign material other than the liquid of suspension as is normally the object of classic liposomes. Hence, preferably, the liposomes of the present invention will contain an aqueous phase identical or similar to the aqueous phase of the solution itself. Then air or a gas is introduced into the liposome solution so that a

00000001.071507

suspension of microbubbles will form, said suspension being stabilized by the presence of the surfactants in lamellar form. Notwithstanding, the material making the liposome walls can be modified within the scope of the present invention, for instance by covalently grafting thereon foreign molecules designed for specific purposes as will be explained later.

The preparation of liposome solutions has been abundantly discussed in many publications, e.g. US-A- 4,224,179 and WO-A-88/09165 and all citations mentioned therein. This prior art is used here as reference for exemplifying the various methods suitable for converting film forming tensides into lamellar form. Another basic reference by M.C. Woodle and D. Papahadjopoulos is found in "Methods in Enzymology" 171 (1989), 193.

For instance, in a method disclosed in D.A. Tyrrell et al, Biochimica & Biophysica Acta 457 (1976), 259-302, a mixture of a lipid and an aqueous liquid carrier is subjected to violent agitation and thereafter sonicated at acoustic or ultrasonic frequencies at room or elevated temperature. In the present invention, it has been found that sonication without agitation is convenient. Also, an apparatus for making liposomes, a high pressure homogenizer such as the Microfluidizer[®], which can be purchased from Microfluidics Corp., Newton, MA 02164 USA, can be used advantageously. Large volumes of liposome solutions can be prepared with this apparatus under pressures which can reach 600-1200 bar.

In another method, according to the teaching of GB-A-2,134,869 (Squibb), microparticles (10 μ m or less) of a hydro-soluble carrier solid (NaCl, sucrose, lactose and other carbohydrates) are coated with an amphipatic agent; the dissolution of the coated carrier in an aqueous phase will yield liposomic vesicles. In GB-A- 2,135,647 insoluble particles, e.g. glass or resin microbeads are coated by moistening in a solution of a lipid in an organic solvent followed by removal of the solvent by evaporation. The lipid coated microbeads are thereafter contacted with an aqueous carrier phase, whereby liposomic vesicles will form in that carrier phase.

0803371.071597

08893371.071597

The introduction of air or gas into a liposome solution in order to form therein a suspension of microbubbles can be effected by usual means, inter alia by injection, that is, forcing said air or gas through tiny orifices into the liposome solution, or simply dissolving the gas in the solution by applying pressure and thereafter suddenly releasing the pressure. Another way is to agitate or sonicate the liposome solution in the presence of air or an entrappable gas. Also one can generate the formation of a gas within the solution of liposomes itself, for instance by a gas releasing chemical reaction, e.g. decomposing a dissolved carbonate or bicarbonate by acid. The same effect can be obtained by dissolving under pressure a low boiling liquid, for instance butane, in the aqueous phase and thereafter allowing said liquid to boil by suddenly releasing the pressure.

Notwithstanding, an advantageous method is to contact the dry surfactant in lamellar or thin film form with air or an adsorbable or entrappable gas before introducing said surfactant into the liquid carrier phase. In this regard, the method can be derived from the technique disclosed in GB-A-2,135,647, i.e. solid microparticles or beads are dipped in a solution of a film forming surfactant (or mixture of surfactants) in a volatile solvent, after which the solvent is evaporated and the beads are left in contact with air (or an adsorbable gas) for a time sufficient for that air to become superficially bound to the surfactant layer. Thereafter, the beads coated with air filled surfactant are put into a carrier liquid, usually water with or without additives, whereby air bubbles will develop within the liquid by gentle mixing, violent agitation being entirely unnecessary. Then the solid beads can be separated, for instance by filtration, from the microbubble suspension which is remarkably stable with time.

Needless to say that, instead of insoluble beads or spheres, one may use as supporting particles water soluble materials like that disclosed in GB-A- 2,134,869 (carbohydrates or hydrophilic polymers), whereby said supporting particles will eventually dissolve and final separation of a solid becomes un-

In a variant of the method, one may also start with dehydrated liposomes, i.e. liposomes which have been prepared normally by means of conventional techniques in the form of aqueous solutions and thereafter dehydrated by usual means, e.g. such as disclosed in US-A- 4,229,360 also incorporated herein as reference. One of the methods for dehydrating liposomes recommended in this reference is freeze-drying (lyophilization), i.e. the liposome solution is frozen and dried by evaporation (sublimation) under reduced pressure. Prior to effecting freeze-drying, a hydrophilic stabilizer compound is dissolved in the solution, for instance a carbohydrate like lactose or sucrose or a hydrophilic polymer like dextran, starch, PVP, PVA and the like. This is useful in the present invention since such hydrophilic compounds also aid in homogenizing the microbubbles size distribution and enhance stability under storage. Actually making very dilute aqueous solutions (0.1 - 10% by weight) of freeze-dried liposomes stabilized with, for instance, a 5:1 to 10:1 weight ratio of lactose to lipid enables to produce aqueous microbubbles suspensions counting 10^8 - 10^9 microbubbles/ml (size distribution mainly 0.5 - 10 μ m) which are stable for at least a month (and probably much longer) without significant observable change. And this is obtained by simple dissolution of the air-stored dried liposomes without shaking or any violent agitation. Furthermore, the freeze-drying technique under reduced pressure is very useful because it permits, after drying, to restore the pressure above the dried liposomes with any entrappable gas, i.e. nitrogen, CO₂, argon, methane, freon, etc., whereby after dissolution of the liposomes processed under such conditions suspensions of microbubbles containing the above gases are obtained.

Microbubbles: suspensions formed by applying gas pressure on a dilute solution of laminated lipids in water (0.1 - 10% by weight) and thereafter suddenly releasing the pressure have an even higher bubble concentration, e.g. in the order of 10^{10} -

10¹¹ bubbles/ml. However, the average bubble size is somewhat above 10 μ m, e.g. in the 10 - 50 μ m range. In this case, bubble size distribution can be narrowed by centrifugation and layer decantation.

The tensides or surfactants which are convenient in this invention can be selected from all amphipatic compounds capable of forming stable films in the presence of water and gases. The preferred surfactants which can be laminarized include the lecithins (phosphatidyl-choline) and other phospholipids, inter alia phosphatidic acid (PA), phosphatidyl-inositol phosphatidyl-ethanolamine (PE), phosphatidyl-serine (PS), phosphatidyl-glycerol (PG), cardiolipin (CL), sphingomyelins, the plasmogens, the cerebroside, etc. Examples of suitable lipids are the phospholipids in general, for example, natural lecithins, such as egg lecithin or soya bean lecithin, or synthetic lecithins such as saturated synthetic lecithins, for example, dimyristoyl phosphatidyl choline, dipalmitoyl phosphatidyl choline or distearoyl phosphatidyl choline or unsaturated synthetic lecithins, such as dioleoyl phosphatidyl choline or dilinoleoyl phosphatidyl choline, with egg lecithin or soya bean lecithin being preferred. Additives like cholesterol and other substances (see below) can be added to one or more of the foregoing lipids in proportions ranging from zero to 50% by weight.

Such additives may include other surfactants that can be used in admixture with the film forming surfactants and most of which are recited in the prior art discussed in the introduction of this specification. For instance, one may cite free fatty acids, esters of fatty acids with polyoxyalkylene compounds like polyoxypropylene glycol and polyoxyethylene glycol; ethers of fatty alcohols with polyoxyalkylene glycols; esters of fatty acids with polyoxyalkylated sorbitan; soaps; glycerol-polyalkylene stearate; glycerol-polyoxyethylene ricinoleate; homo- and copolymers of polyalkylene glycols; polyethoxylated soya-oil and castor oil as well as hydrogenated derivatives; ethers and esters of sucrose or other carbohydrates with fatty acids, fatty alcohols, these being optionally polyoxyalkylated; mono-, di- and triglycerides of saturated or unsaturated fatty acids; glyce-

0803271.071597

The total amount of surfactants relative to the aqueous carrier liquid is best in the range of 0.01 to 25% by weight but quantities in the range 0.5 - 5% are advantageous because one always tries to keep the amount of active substances in an injectable solution as low as possible, this being to minimize the introduction of foreign materials into living beings even when they are harmless and physiologically compatible.

a) substances which are known to provide a negative charge on liposomes, for example, phosphatidic acid, phosphatidylglycerol or dicetyl phosphate;

c) substances known to affect the physical properties of the lipid films in a more desirable way; for example, capro-lactam and/or sterols such as cholesterol, ergosterol, phytosterol, sitosterol, sitosterol pyroglutamate, 7-dehydro-cholesterol or lanosterol, may affect lipid films rigidity;

The aqueous carrier in this invention is mostly water with possibly small quantities of physiologically compatible liquids such as isopropanol, glycerol, hexanol and the like (see for instance EP-A- 52.575). In general the amount of the organic hydrosoluble liquids will not exceed 5 - 10% by weight.

The present composition may also contain dissolved or suspended therein hydrophilic compounds and polymers defined generally under the name of viscosity enhancers or stabilizers. Although the presence of such compounds is not compulsory for ensuring stability to the air or gas bubbles with time in the present dispersions, they are advantageous to give some kind of

"body" to the solutions. When desired, the upper concentrations of such additives when totally innocuous can be very high, for instance up to 80 - 90% by weight of solution with Iopamidol and other iodinated X-ray contrast agents. However with other viscosity enhancers like for instance sugars, e.g. lactose, sucrose, maltose, galactose, glucose, etc. or hydrophilic polymers like starch, dextran, polyvinyl alcohol, polyvinyl-pyrrolidone, dextrans, xanthan or partly hydrolyzed cellulose oligomers, as well as proteins and polypeptides, the concentrations are best between about 1 and 40% by weight, a range of about 5 - 20% being preferred.

Like in the prior art, the injectable compositions of this invention can also contain physiologically acceptable electrolytes; an example is an isotonic solution of salt.

The present invention naturally also includes dry storable pulverulent blends which can generate the present microbubble containing dispersions upon simple admixing with water or an aqueous carrier phase. Preferably such dry blends or formulations will contain all solid ingredients necessary to provide the desired microbubbles suspensions upon the simple addition of water, i.e. principally the surfactants in lamellar form containing trapped or adsorbed therein the air or gas required for microbubble formation, and accessorially the other non-film forming surfactants, the viscosity enhancers and stabilizers and possibly other optional additives. As said before, the air or gas entrapment by the laminated surfactants occurs by simply exposing said surfactants to the air (or gas) at room or super-atmospheric pressure for a time sufficient to cause said air or gas to become entrapped within the surfactant. This period of time can be very short, e.g. in the order of a few seconds to a few minutes although over-exposure, i.e. storage under air or under a gaseous atmosphere is in no way harmful. What is important is that air can well contact as much as possible of the available surface of the laminated surfactant, i.e. the dry material should preferably be in a "fluffy" light flowing condition. This is precisely this condition which results from the freeze-drying of an aqueous solution of liposomes and hydro-

0893371.071097

philic agent as disclosed in US-A- 4,229,360.

In general, the weight ratio of surfactants to hydrophilic viscosity enhancer in the dry formulations will be in the order of 0.1:10 to 10:1, the further optional ingredients, if any, being present in a ratio not exceeding 50% relative to the total of surfactants plus viscosity enhancers.

The dry blend formulations of this invention can be prepared by very simple methods. As seen before, one preferred method is to first prepare an aqueous solution in which the film forming lipids are laminarized, for instance by sonication, or using any conventional technique commonly used in the liposome field, this solution also containing the other desired additives, i.e. viscosity enhancers, non-film forming surfactants, electrolyte, etc., and thereafter freeze drying to a free flowable powder which is then stored in the presence of air or an entrappable gas.

The dry blend can be kept for any period of time in the dry state and sold as such. For putting it into use, i.e. for preparing a gas or air microbubble suspension for ultrasonic imaging, one simply dissolves a known weight of the dry pulverulent formulation in a sterile aqueous phase, e.g. water or a physiologically acceptable medium. The amount of powder will depend on the desired concentration of bubbles in the injectable product, a count of about 10^8 - 10^9 bubbles/ml being generally that from making a 5 - 20% by weight solution of the powder in water. But naturally this figure is only indicative, the amount of bubbles being essentially dependent on the amount of air or gas trapped during manufacture of the dry powder. The manufacturing steps being under control, the dissolution of the dry formulations will provide microbubble suspensions with well reproducible counts.

The resulting microbubble suspensions (bubble in the 0.5 - 10 μ m range) are extraordinarily stable with time, the count originally measured at start staying unchanged or only little changed for weeks and even months; the only observable change is a kind of segregation, the larger bubbles (around 10 μ m) tending to rise faster than the small ones.

08092371.071597

Another advantage of the bubbles of this invention versus the microcapsules of the prior art surrounded by a rigid but breakable membrane which may irreversibly fracture under stress is that when the present suspensions are subject to sudden pressure changes, the present bubbles will momentarily contract elastically and then resume their original shape when the pressure is released. This is important in clinical practice when the microbubbles are pumped through the heart and therefore are exposed to alternating pressure pulses.

The bubble suspensions of the present invention are also useful in other medical/diagnostic applications where it is desirable to target the stabilized microbubbles to specific sites in the body following their injection, for instance to thrombi present in blood vessels, to atherosclerotic lesions (plaques) in arteries, to tumor cells, as well as for the

diagnosis of altered surfaces of body cavities, e.g. ulceration sites in the stomach or tumors of the bladder. For this, one can bind monoclonal antibodies tailored by genetic engineering, antibody fragments or polypeptides designed to mimic antibodies, bioadhesive polymers, lectins and other site-recognizing molecules to the surfactant layer stabilizing the microbubbles. Thus monoclonal antibodies can be bound to phospholipid bilayers by the method described by L.D. Leserman, P. Machy and J. Barbet ("Liposome Technology vol. III" p. 29 ed. by G. Gregoriadis, CRC Press 1984). In another approach a palmitoyl antibody is first synthesized and then incorporated in phospholipid bilayers following L. Huang, A. Huang and S.J. Kennel ("Liposome Technology vol. III" p. 51 ed. by G. Gregoriadis, CRC Press 1984). Alternatively, some of the phospholipids used in the present invention can be carefully selected in order to obtain preferential uptake in organs or tissues or increased half-life in blood. Thus GM1 gangliosides- or phosphatidylinositol-containing liposomes, preferably in addition to cholesterol, will lead to increased half-lives in blood after intravenous administration in analogy with A. Gabizon, D. Papahadjopoulos, Proc. Natl Acad. Sci USA 85 (1988) 6949.

The gases in the microbubbles of the present invention can include, in addition to current innocuous physiologically acceptable gases like CO_2 , nitrogen, N_2O , methane, butane, freon and mixtures thereof, radioactive gases such as ^{133}Xe or ^{81}Kr are of particular interest in nuclear medicine for blood circulation measurements, for lung scintigraphy etc.

The following Examples illustrate the invention on a practical stand point.

Echogenic measurements

Echogenicity measurements were performed in a pulse - echo system made of a plexiglas specimen holder (diameter 30 mm) and a transducer holder immersed in a constant temperature water bath, a pulser-receiver (Accutron M3010S) with for the receiving part an external pre-amplifier with a fixed gain of 40 dB and an internal amplifier with adjustable gain from -40 to +40 dB. A

10MHz low-pass filter was inserted in the receiving part to improve the signal to noise ratio. The A/D board in the IBM PC was a Sonotek STR 832. Measurements were carried out at 2.25, 3.5, 5 and 7.5 MHz.

Example 1

A liposome solution (50 mg lipids per ml) was prepared in distilled water by the REV method (see F. Szoka Jr. and D. Papahadjopoulos, Proc. Natl. Acad. Sci. USA 75 (1978) 4194) using hydrogenated soya lecithin (NC 95 H, Nattermann Chemie, Köln, W. Germany) and dicetylphosphate in a molar ratio 9/1. This liposome preparation was extruded at 65°C (to calibrate the vesicle size) through a 1 µm polycarbonate filter (Nucleopore). Two ml of this solution were admixed with 5 ml of a 75% iopamidol solution in water and 0.4 ml of air and the mixture was forced back and forth through a two syringe system as disclosed in DE-A-3529195, while maintaining continuously a slight over-pressure. This resulted in the formation of a suspension of microbubbles of air in the liquid (10^5 - 10^6 bubbles per ml, bubble size 1-20 µm as estimated by light microscopy) which was stable for several hours at room temperature. This suspension gave a strong echo signal when tested by ultrasonic echography at 7.5, 5, 3.5 and 2.25 MHz.

Example 2

A distilled water solution (100 ml) containing by weight 2% of hydrogenated soya lecithin and dicetylphosphate in a 9/1 molar ratio was sonicated for 15 min at 60-65°C with a Branson probe sonifier (Type 250).

After cooling, the solution was centrifuged for 15 min at 10,000 g and the supernatant was recovered and lactose added to make a 7.5% b.v. solution. The solution was placed in a tight container in which a pressure of 4 bar of nitrogen was established for a few minutes while shaking the container. Afterwards, the pressure was released suddenly whereby a highly concentrated bubble suspension was obtained (10^{10} - 10^{11} bubbles/ml). The size distribution of the bubbles was however

vider than in Example 1, i.e. from about 1 to 50 μm . The suspension was very stable but after a few days a segregation occurred in the standing phase, the larger bubbles tending to concentrate in the upper layers of the suspension.

Example 3

Twenty g of glass beads (diameter about 1 mm) were immersed into a solution of 100 mg of dipalmitoylphosphatidylcholine (Fluka A.G. Buchs) in 10 ml of chloroform. The beads were rotated under reduced pressure in a rotating evaporator until all CHCl_3 had escaped. Then the beads were further rotated under atmospheric pressure for a few minutes and 10 ml of distilled water were added. The beads were removed and a suspension of air microbubbles was obtained which was shown to contain about 10^6 bubbles/ml after examination under the microscope. The average size of the bubbles was about 3 - 5 μm . The suspension was stable for several days at least.

Example 4

A hydrogenated soya lecithin/dicetylphosphate suspension in water was laminarized using the REV technique as described in Example 1. Two ml of the liposome preparation were added to 8 ml of 15% maltose solution in distilled water. The resulting solution was frozen at -30°C , then lyophilized under 0.1 Torr. Complete sublimation of the ice was obtained in a few hours. Thereafter, air pressure was restored in the evacuated container so that the lyophilized powder became saturated with air in a few minutes.

The dry powder was then dissolved in 10 ml of sterile water under gentle mixing, whereby a microbubble suspension (10^8 - 10^9 microbubbles per ml, dynamic viscosity $< 20 \text{ mPa.s}$) was obtained. This suspension containing mostly bubbles in the 1-5 μm range was stable for a very long period, as numerous bubbles could still be detected after 2 months standing. This microbubble suspension gave a strong response in ultrasonic echography. If in this example the solution is frozen by spraying in air at -30 to -70°C to obtain a frozen snow instead of a monolithic block

0000071 074507

and the snow is then evaporated under vacuum, excellent results are obtained.

Example 5

Two ml samples of the liposome solution obtained as described in Example 4 were mixed with 10 ml of an 5% aqueous solution of gelatin (sample 5A), human albumin (sample 5B), dextran (sample 5C) and iopamidol (sample 5D). All samples were lyophilized. After lyophilization and introduction of air, the various samples were gently mixed with 20 ml of sterile water. In all cases, the bubble concentration was above 10^8 bubbles per ml and almost all bubbles were below $10\ \mu\text{m}$. The procedure of the foregoing Example was repeated with 9 ml of the liposome preparation (450 mg of lipids) and only one ml of a 5% human albumin solution. After lyophilization, exposure to air and addition of sterile water (20 ml), the resulting solution contained 2×10^8 bubbles per ml, most of them below $10\ \mu\text{m}$.

Example 6

Lactose (500 mg), finely milled to a particle size of 1-3 μm , was moistened with a chloroform (5 ml) solution of 100 mg of dimyristoylphosphatidylcholine/cholesterol/dipalmitoylphosphatidic acid (from Fluka) in a molar ratio of 4:1:1 and thereafter evaporated under vacuum in a rotating evaporator. The resulting free flowing white powder was rotated a few minutes under nitrogen at normal pressure and thereafter dissolved in 20 ml of sterile water. A microbubble suspension was obtained with about 10^5 - 10^6 microbubbles per ml in the 1-10 μm size range as ascertained by observation under the microscope. In this Example, the weight ratio of coated surfactant to water-soluble carrier was 1:5. Excellent results (10^7 - 10^8 microbubbles/ml) are also obtained when reducing this ratio to lower values, i.e. down to 1:20, which will actually increase the surfactant efficiency for the intake of air, that is, this will decrease the weight of surfactant necessary for producing the same bubble count.

Example 7

An aqueous solution containing 2% of hydrogenated soya lecithin and 0.4% of Pluronic[®] F68 (a non ionic polyoxyethylene-polyoxypropylene copolymer surfactant) was sonicated as described in Example 2. After cooling and centrifugation, 5 ml of this solution were added to 5 ml of a 15% maltose solution in water. The resulting solution was frozen at -30°C and evaporated under 0.1 Torr. Then air pressure was restored in the vessel containing the dry powder. This was left to stand in air for a few seconds, after which it was used to make a 10% by weight aqueous solution which showed under the microscope to be a suspension of very tiny bubbles (below 10 μ m); the bubble concentration was in the range of 10^7 bubbles per ml. This preparation gave a very strong response in ultrasonic echography at 2.25, 3.5, 5 and 7.5 MHz.

Example 8

Two-dimensional echocardiography was performed in an experimental dog following peripheral vein injection of 0.1-2 ml of the preparation obtained in Example 4. Opacification of the left heart with clear outlining of the endocardium was observed, thereby confirming that the microbubbles (or at least a significant part of them) were able to cross the pulmonary capillary circulation.

Example 9

A phospholipid/maltose lyophilized powder was prepared as described in Example 4. However, at the end of the lyophilization step, a ^{133}Xe containing gas mixture was introduced in the evacuated container instead of air. A few minutes later, sterile water was introduced and after gentle mixing a microbubble suspension containing ^{133}Xe in the gas phase was produced. This microbubble suspension was injected into living bodies to undertake investigations requiring use of ^{133}Xe as tracer. Excellent results were obtained.

00000071.071507

Example 10 (comparative)

In US-A-4,900,540, Ryan et al disclose gas filled liposomes for ultrasonic investigations. According to the citation, liposomes are formed by conventional means but with the addition of a gas or gas precursor in the aqueous composition forming the liposome core (col. 2, lines 15-27).

Using a gas precursor (bicarbonate) is detailed in Examples 1 and 2 of the reference. Using an aqueous carrier with an added gas for encapsulating the gas in the liposomes (not exemplified by Ryan et al) will require that the gas be in the form of very small bubbles, i.e. of size similar or smaller than the size of the liposome vesicles.

Aqueous media in which air can be entrapped in the form of very small bubbles (2.5-5 μm) are disclosed in M.W. Keller et al, J. Ultrasound Med. 5 (1986), 413-498.

A quantity of 126 mg of egg lecithin and 27 mg of cholesterol were dissolved in 9 ml of chloroform in a 200 ml round bottom flask. The solution of lipids was evaporated to dryness on a Rotavapor whereby a film of the lipids was formed on the walls of the flask. A 10 ml of a 50% by weight aqueous dextrose solution was sonicated for 5 min according to M.W. Keller et al (ibid) to generate air microbubbles therein and the sonicated solution was added to the flask containing the film of lipid, whereby hand agitation of the vessel resulted into hydration of the phospholipids and formation of multilamellar liposomes within the bubbles containing carrier liquid.

After standing for a while, the resulting liposome suspension was subjected to centrifugation under 5000 g for 15 min to remove from the carrier the air not entrapped in the vesicles. It was also expected that during centrifugation, the air filled liposomes would segregate to the surface by buoyancy.

After centrifugation the tubes were examined and showed a bottom residue consisting of agglomerated dextrose filled liposomes and a clear supernatant liquid with substantially no bubble left. The quantity of air filled liposomes having risen by buoyancy was negligibly small and could not be ascertained.

0000071.071527

An injectable contrast composition was prepared according to Ryan (US-A-4,900,540, col. 3, Example 1). Egg lecithin (126 mg) and cholesterol (27 mg) were dissolved in 9 ml of diethylether. To the solution were added 3 ml of 0.2 molar aqueous bicarbonate and the resulting two phase systems was sonicated until becoming homogeneous. The mixture was evaporated in a Rotavapor apparatus and 3 ml of 0.2 molar aqueous bicarbonate were added.

A 1 ml portion of the liposome suspension was injected into the jugular vein of an experimental rabbit, the animal being under condition for heart ultrasonic imaging using an Acuson 128-XP5 ultrasonic imager (7.5 transducer probe for imaging the heart). The probe provided a cross-sectional image of the right and left ventricles (mid-papillary muscle). After injection, a light and transient (a few seconds) increase in the outline of the right ventricle was observed. The effect was however much inferior to the effect observed using the preparation of Example 4. No improvement of the imaging of the left ventricle was noted which probably indicates that the CO₂ loaded liposomes did not pass the pulmonary capillaries barrier.

CLAIMS

1. A composition adapted for injection into the blood-stream and body cavities of living beings, e.g. for the purpose of ultrasonic echography, consisting of a suspension of air or gas microbubbles in a physiologically acceptable aqueous carrier phase comprising from about 0.01 to about 20% by weight of one or more dissolved or dispersed surfactants, characterized in that at least one of the surfactants is a film forming surfactant present in the composition at least partially in lamellar or laminar form.

2. The composition of claim 1, characterized in that the lamellar surfactant is in the form of mono- or pluri-molecular membrane layers.

3. The composition of claim 1, characterized in that the lamellar surfactant is in the form of liposome vesicles.

4. The composition of claim 1, characterized in that it essentially consists of a liposome solution containing air or gas microbubbles developed therein.

5. The composition of claim 4, characterized in that the size of most of both liposomes and microbubbles is below 50 μm , preferably below 10 μm .

6. The composition of claim 1, containing about $10^8 - 10^9$ bubbles of 0.5 - 10 μm size/ml, said concentration showing little or substantially no variability under storage for at least a month.

7. The composition of claim 1, characterized in that the surfactants are selected from phospholipids including the lecithins such as phosphatidic acid, phosphatidyl-choline, phosphatidyl-ethanolamine, phosphatidyl-serine, phosphatidyl-glycerol phosphatidyl-inositol, cardiolipin and sphingomyelin.

8. The composition of claim 7, characterized in further containing substances affecting the properties of liposomes selected from phosphatidyl-glycerol, dicetyl-phosphate, cholesterol, ergosterol, phytosterol, sitosterol, lanosterol, tocopherol, propyl gallate, ascorbyl palmitate and butyated hydroxy-toluene.

15. The method of claim 11, in which the conversion of step (a) is effected by coating the surfactant onto particles of soluble or insoluble materials; step (b) is effected by letting the coated particles stand for a while under air or a gas; and

25. The use of the injectable composition of claims 1-10 for transporting in the blood-stream or body cavities bubbles of

foreign gases active therapeutically or diagnostically.

26. The composition of claim 4, in which the surfactant comprises, bound thereto, bioactive species designed for specific targeting purposes, e.g. for immobilizing the bubbles in specifically defined sites in the circulatory system, or in organs, or in tissues.

27. The composition of claim 4, in which the surfactant comprises, bound thereto, bioactive species selected from monoclonal antibodies, antibody fragments or polypeptides designed to mimic antibodies, bioadhesive polymers, lectins and other receptor recognizing molecules.

2025 RELEASE UNDER E.O. 14176

ABSTRACT

Gas or air filled microbubble suspensions in aqueous phases usable as imaging contrast agents in ultrasonic echography. They contain laminarized surfactants and, optionally, hydrophilic stabilizers. The laminarized surfactants can be in the form of liposomes. The suspensions are obtained by exposing the laminarized surfactants to air or a gas before or after admixing with an aqueous phase.

0803374.071507

1201-3

**RULE 63 (37 C.F.R. 1.63)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

STABLE MICROBUBBLES SUSPENSIONS INJECTABLE INTO LIVING ORGANISMS

the specification of which (check applicable box(es)):

☐ is attached hereto.

☐ was filed on as U.S. Application Serial No.

☒ was filed as PCT international application No. PCT/EP91/00620 on 2 April 1991

and (if applicable to U.S. or PCT application) was amended on

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 C.F.R. 1.56(a). I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Prior Foreign Application(s):

Application Number

Country

Day/Month/Year Filed

90810262.7

Europe

2 April 1990

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. 1.56(a) which occurred between the filing date of the prior applications and the national or PCT international filing date of this application:

Prior U.S./PCT Application(s):

Application Serial No.

Day/Month/Year Filed

Status: patented,
pending, abandoned

PCT/EP91/00620

2 April 1991

Pending

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

And I hereby appoint NIXON & VANDERHYE P.C., 2200 Clarendon Boulevard, 14th Floor, Arlington, Virginia 22201, telephone number (703) 875-0400 (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25640; Robert A. Vanderhye, 27076; James T. Hosner, 30184; Robert W. Faria, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan R. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Hitchard, 29009; Duane M. Byers, 33363; Paul J. Henon, 33626; Jeffrey H. Nelson, 30481.

- 1) Inventor's Signature Michel Schneider Date 11 novembre 1991
 Inventor's Name (typed) Michel SCHNEIDER French
 First Middle Initial Family Name Citizenship
 Residence (City) Troinex (State/Foreign Country) Switzerland
 Post Office Address Douane du Moulin, 34 route d'Annecy, CH - 1256 Troinex, Switzerland Zip Code
- 2) Inventor's Signature Daniel Poichon Date 11 novembre 1991
 Inventor's Name (typed) Daniel BICHON French
 First Middle Initial Family Name Citizenship
 Residence (City) Montpellier (State/Foreign Country) France
 Post Office Address 34 rue Lacanal, F - 34000 Montpellier, France Zip Code
- 3) Inventor's Signature Philippe Bussat Date 11 novembre 1991
 Inventor's Name (typed) Philippe BUSSAT French
 First Middle Initial Family Name Citizenship
 Residence (City) Collonges S/Saleve (State/Foreign Country) France
 Post Office Address 155 chemin de Corbar, F - 74160 Collonges S/Saleve, France Zip Code

FOR ADDITIONAL INVENTORS, check box (X) and attach sheet with same information and signature and date for each.

1201-3

Nixon & Vanderhye P.C. (8/90)

RULE 63 (37 C.F.R. 1.63)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

STABLE MICROBUBBLES SUSPENSIONS INJECTABLE INTO LIVING ORGANISMS

the specification of which (check applicable box(es)):

☐ is attached hereto.

☐ was filed on as U.S. Application Serial No. _____

☒ was filed as PCT international application No. PCT/EP91/00620 on 2 Apr 1991

and (if applicable to U.S. or PCT application) was amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 C.F.R. 1.56(a). I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Prior Foreign Application(s):

Application Number

Country

Day/Month/Year Filed

90810262.7

Europe

2 April 1990

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. 1.56(a) which occurred between the filing date of the prior applications and the national or PCT international filing date of this application:

Prior U.S./PCT Application(s):

Application Serial No.

Day/Month/Year Filed

Status: patented,
pending, abandoned

PCT/EP91/00620

+

2 Apr 1991

Pending

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge which willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

And I hereby appoint NIXON & VANDERHYE P.C., 2200 Clarendon Boulevard, 14th Floor, Arlington, Virginia 22201, telephone number (703) 875-0400 (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25640; Robert A. Vanderhye, 27076; James T. Bosmer, 30184; Robert M. Paris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Hitchard, 29009; Duane M. Byers, 33363; Paul J. Ronon, 33626; Jeffrey B. Nelson, 30481.

- 4) Inventor's Signature Jerome Eugénie Date 11 novembre 1991
- | Inventor's Name (typed) | First | Middle Initial | Family Name | French | Citizenship |
|-------------------------|--|----------------|-------------|-------------------------|-------------|
| Jerome | | | PUGNIER | French | |
| Residence (City) | Le Chable-Beaumont | | | (State/Foreign Country) | |
| Post Office Address | Place de l'Ancienne Mairie, P - 74160 Le Chable-Beaumont, France | | | France | Zip Code |
- 5) Inventor's Signature Eva Hylt-Sutherland Date 22 octobre 91
- | Inventor's Name (typed) | First | Middle Initial | Family Name | Swiss | Citizenship |
|--|--|----------------|-----------------|-------------------------|-------------|
| Eva | | | HYLT-SUTHERLAND | Swiss | |
| Residence (City) | Geneve - WIESBADEN | | | (State/Foreign Country) | |
| Post Office Address | 4 Avenue Frederic Sorot, CH - 1203 Geneve, Switzerland | | | Switzerland | GERMANY |
| Flaene Weinbergstrasse 1, D - 6200 WIESBADEN Germany | | | | | |

FOR ADDITIONAL INVENTORS, check box 1 XI and attach sheet with same information and signature and date for each.